Top 3 Health Care Stocks That May Rocket Higher In July

by | Jul 6, 2026 | General

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Evommune Inc (NYSE:EVMN)

  • On June 29, Evommune disclosed that its investigational therapy EVO756 failed to meet the primary endpoint in a mid-stage study in patients with chronic spontaneous urticaria (CSU). The update prompted the clinical-stage biotechnology company to discontinue development of the drug candidate for the indication. The company’s stock fell around 46% over the past five days and has a 52-week low of $12.51.
  • RSI Value: 29.6
  • EVMN Price Action: Shares of Evommune rose 1.1% to close at $12.96 on Thursday.
  • Benzinga Pro’s charting tool helped identify the trend in EVMN stock.

Anbio Biotechnology (NASDAQ:NNNN) 

  • Anbio Biotechnology, during April, reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024. Net income surged to $6.4 million, up from $2.37 million, while earnings from continuing operations jumped to 15 cents per share from 6 cents. The company’s stock fell around 17% over the past five days and has a 52-week low of $10.50.
  • RSI Value: 29.1
  • NNNN Price Action: Shares of Anbio Biotechnology rose 2.9% to close at $12.70 on Thursday.
  • Edge Stock Ratings: 0.81 Momentum score with Value at 3131.

Nautilus Biotechnology Inc (NASDAQ:NAUT)

  • On April 28, Nautilus Biotechnology posted a first-quarter loss of 12 cents per share. “In Q1, we made measurable progress toward commercialization, with early customer engagement reinforcing the value of our platform in real-world research settings,” said Sujal Patel, CEO of Nautilus Biotechnology. “We also advanced our broadscale capabilities, including development of a next-generation assay format designed to improve probe compatibility, performance, and scalability. Together with the addition of experienced sales leadership, these efforts position us to scale Early Access and progress toward full commercial availability.” The company’s stock fell around 22% over the past five days and has a 52-week low of $0.62.
  • RSI Value: 27
  • NAUT Price Action: Shares of Nautilus Biotechnology fell 6% to close at $1.73 on Thursday.
  • Benzinga Pro’s signals feature notified of a potential breakout in NAUT shares.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock